Eyevensys Overview

  • Founded
  • 2008

Founded
  • Status
  • Private

  • Employees
  • 17

Employees
  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $11.8M

  • Investors
  • 12

Eyevensys General Information

Description

Developer of therapeutic proteins intended to address the critical unmet needs in ophthalmology. The company's proteins treat both short and long-term therapeutic outcomes like chronic non-infectious uveitis, degenerative retinal diseases, retinal vascular diseases, and macular oedema, as well as enhance compliance, ocular bioavailability, and tolerability, enabling physicians to treat various eye diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Biopark
  • 11 Rue Watt Bat B
  • 75013 Paris
  • France
+33 01 00 00 00 00

Eyevensys Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eyevensys Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B) 04-Aug-2021 $11.8M 0000 000.00 Completed Generating Revenue
4. Later Stage VC (Series B) 08-Jan-2020 000.00 000.00 00000 Completed Generating Revenue
3. Later Stage VC (Series A) 27-Sep-2016 000.00 000.00 000.00 Completed Generating Revenue
2. Early Stage VC 11-Apr-2013 $259K $2.35M Completed Startup
1. Early Stage VC 14-May-2012 $2.09M $2.09M 000.00 Completed Startup
To view Eyevensys’s complete valuation and funding history, request access »

Eyevensys Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Shares B1 000,000 00.000000 000.00 000.00 00 000.00 00.000
Series B 000,000 00.000000 0000.00 0000.00 00 0000.00 0.000
B Shares 000,000 00.000000 000.00 000.00 00 000.00 00.000
B Shares 000,000 00.000000 000.00 000.00 00 000.00 00.000
Series A 407,297 $0.011827 $26.13 $26.13 1x $26.13 14.95%
Ordinary 21,242 $0.011827 $89.08 $89.08 1x $89.08 0.78%
To view Eyevensys’s complete cap table history, request access »

Eyevensys Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of therapeutic proteins intended to address the critical unmet needs in ophthalmology. The company's proteins
Drug Discovery
Paris, France
17 As of 2022
0000
00.00 0000-00-00
00000000000 0000

000 00

ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris
0000000000000
Ann Arbor, MI
00 As of 0000
000.00
00000000000 000.00

000000

boris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate v
0000 000000000
Paris, France
00 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eyevensys Competitors (19)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI 00 000.00 00000000000 000.00
0000000000000 Venture Capital-Backed Paris, France 00 000.00 0000000000 0 000.00
0000 000000000000 Venture Capital-Backed San Diego, CA 0 0000 00000000000 0000
0000000 0000000000 Formerly VC-backed Redwood City, CA 000 00000 00000000000 00000
0000000 Venture Capital-Backed Cambridge, United Kingdom 00 00.000 0000000000 0 00.000
You’re viewing 5 of 19 competitors. Get the full list »

Eyevensys Patents

Eyevensys Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2982225-A1 Electroporation device Pending 14-Apr-2015 0000000000
JP-6845154-B2 Electroporation device Active 14-Apr-2015 000000000
EP-3081198-A1 Elektroporation device for the eye with a support and with a needle electrode Withdrawn 14-Apr-2015 000000000 0
AU-2016247369-B2 Electroporation device for the eye with a support and with a needle electrode Active 14-Apr-2015 000000000 0
AU-2016247369-A1 Electroporation device for the eye with a support and with a needle electrode Granted 14-Apr-2015 A61N1/327
To view Eyevensys’s complete patent history, request access »

Eyevensys Executive Team (7)

Name Title Board Seat Contact Info
Patricia Zilliox Ph.D Chief Executive Officer & President
Thierry Bordet Ph.D Chief Scientific Officer
Gina Pinto Finance & Administration Director
Francine Behar-Cohen MD Founder & Chief Innovation Officer
Ronald Buggage MD Chief Medical Officer
You’re viewing 5 of 7 executive team members. Get the full list »

Eyevensys Board Members (14)

Name Representing Role Since
Catherine Boule Karista (France) Board Observer 000 0000
Chahra Louafi Bpifrance Board Member 000 0000
Dominik Escher Ph.D Pureos Bioventures Board Member 000 0000
François Thomas Ph.D Inserm Transfert Board Observer 000 0000
Frank Kalkbrenner Ph.D Boehringer Ingelheim Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Eyevensys Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eyevensys Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Korea Investment Partners Venture Capital Minority 000 0000 000000 0
GF Securities Investment Bank Minority 000 0000 000000 0
Pureos Bioventures Venture Capital Minority 000 0000 000000 0
Quark Venture Venture Capital Minority 000 0000 000000 0
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »